Clara Olier Garate
Clara Olier Garate
JEFE/A SERVICIO ONCOLOGÍA MÉDICA
Oncología Médicaen/specialities/oncologia-medica
Ver más especialistas en
Madridmadrid
en/medical-staff/oncologo
La Dra. Clara Olier Garate es una reconocida oncóloga, licenciada en Medicina por la Universidad de Navarra. Actualmente, coordina el área de Oncología en el Hospital Ruber Juan Bravo 39, donde ejerce como titular, centrando su asistencia en el cáncer de mama, ginecológico y consejo genético. Su contribución al campo de la oncología se refleja en su publicación más reciente, "HER2 expression dynamics between diagnosis and recurrence in breast cancer using AI and EHR: the RosHER study", en la revista ESMO Real World Data and Digital Oncology, publicada en enero de 2025. Además, la Dra. Olier Garate es miembro del Spanish Group of Medical Oncology (SEOM), una sociedad científica que promueve la investigación y el desarrollo en oncología médica. Su trayectoria profesional y académica la posiciona como una figura influyente en el ámbito de la oncología, comprometida con la mejora continua de los tratamientos y la atención a los pacientes.
Key information
- Latest Publication:Chapter 2.2 “Spinal cord compression” in ONCOSUR Neuro-Oncology Guidelines
- Belongs to:Spanish Group of Oncology Aesthetic Medicine (GEMEON)
Datos del profesional
Hospital Universitario Ruber Juan Bravo
JEFE/A SERVICIO ONCOLOGÍA MÉDICA
Agosto 2025
ICON plc
Director/a Médico
Septiembre 2024
University Hospital Foundation Alcorcón
Facultativo/a esp.
Abril 2008
Estudio
Licenciatura en Medicina
Universidad de Navarra
2003
Otra titulación
Fellowship clínico en Oncología Médica
Otra titulación
Máster de formación permanente en medicina estética
Author of Master in Medical Oncology
Tech University
Enero 2024
Associate professor in Oncology
Rey Juan Carlos University
Agosto 2018
Improving caregivers’ performance and reducing the burden of care through Virtual/Augmented Reality training
Next Generation Funds
2023
Neoadjuvant chemotherapy with nab-paclitaxel in high-risk HER2– breast cancer (ETNA Study)
Phase III open-label study of abemaciclib with standard adjuvant endocrine therapy
CORALLEEN Phase II trial of polychemotherapy or letrozole plus ribociclib
Multicenter Phase III randomized, double-blind, placebo-controlled trial of Denosumab
Observational study in metastatic HR+/HER2– breast cancer patients treated with abemaciclib
Molecular reclassification of early-stage ovarian cancer
Multicenter Phase II study comparing GDC-9545 plus palbociclib versus anastrozole plus palbociclib
Phase III open-label, multicenter study evaluating adjuvant Giredestrant
Phase II randomized study (DIANER Study)
Evaluation of polymorphisms in genes CYP19A1, ABCB1, CYP1A2, CYP2D6 and CYP3A
Retrospective observational study (RosHER)
Observational Non-Post-Authorization Study (RegistEM Study)
Phase III post-neoadjuvant study (SASCIA)
Phase III trial comparing subcutaneous octreotide (CAM2029)
Study targeting the PAM50 HER2-enriched phenotype with enzalutamide
Phase III study of LEE011 or placebo with tamoxifen and goserelin
Phase III MONALEESA-3 study
Review of cyclin-dependent kinase inhibitors in clinical practice
Randomized, double-blind, placebo-controlled trial of neratinib
Phase IIB randomized, multicenter trial evaluating continuation versus discontinuation of temozolomide
Multicenter Phase II study of nivolumab in combination with ipilimumab
Study on the efficacy of Fulvestrant 500 mg
Chapter 2.2 “Spinal cord compression” in ONCOSUR Neuro-Oncology Guidelines
Book Chapter
Chapter 4 in ONCOSUR Sarcoma Treatment Guidelines
Book Chapter
Chapter 5 “Interpretation of current guidelines” in ONCOSUR Neuroendocrine Tumors Guidelines
Book Chapter
Chapters 1.7, 2.3 and 3.1 in ONCOSUR Neuro-Oncology Guidelines
Book Chapter
Clinical and Sociodemographic Determinants of Adherence to WCRF/AICR Recommendations in Breast Cancer Survivors (Health-EpiGEICAM Study)
Journal Article
Correlation between breast cancer subtypes by IHC and n-COUNTER PAM50 assay: a real-world study
Journal Article
CTNI-54: Combined analysis of two randomized studies exploring extended post-radiation temozolomide in newly diagnosed glioblastoma
Journal Article
Dose-finding study of fixed dose rate infusion of gemcitabine in combination with bevacizumab and escalating irinotecan in advanced GI tumors
Journal Article
Drug-induced thrombocytopenia induced by trastuzumab: a special challenge in a curable disease
Journal Article
Epidemiología y factores pronósticos del cáncer de mama
Journal Article
Exploring management and outcomes of elderly glioblastoma patients (GEINO1401/EX-TEM)
Journal Article
Factors Associated with the Selection of First-line Bevacizumab plus Chemotherapy and Clinical Response in HER2– Metastatic Breast Cancer: ONCOSUR AVALOX Study
Journal Article
Fecal calprotectin as a predictor of gastrointestinal immune-related adverse events (CF-19)
Journal Article
Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive advanced breast cancer
Journal Article
HER2 expression dynamics between diagnosis and recurrence in breast cancer using AI and EHR: the RosHER study
Journal Article
Human epidermal growth factor receptor 2 (HER2) expression dynamics between diagnosis and recurrence in patients with breast cancer using artificial intelligence and electronic health records: the RosHER study
Articulo
Hyperalgesia in patients treated with opioids with cancer pain: when more morphine means more pain
Journal Article
Long-term results of the GEINO 1401 trial: Randomizing patients to stop or continue temozolomide until 12 cycles
Journal Article
Macroscopic Extramedullary Hematopoiesis Resembling Hepatic Metastases in Prostate Cancer
Journal Article
Modulation by treatment of tumor infiltrating lymphocytes (TILs) and PDL1 expression in triple-negative breast cancer in the ETNA trial
Journal Article
Mujer de 41 años con tumor de la granulosa ovárica tratado con ketoconazol
Journal Article
Nivolumab monotherapy in previously treated advanced NSCLC in routine practice in Spain
Journal Article
Nuevos tratamientos para el carcinoma renal
Journal Article
ONCOSUR Breast Cancer Treatment Guidelines 2019
Book Chapter
Participation in ONCOSUR Breast Cancer Guidelines 2009
Book Chapter
Phase II randomized, multicenter trial of continuing adjuvant temozolomide beyond 6 cycles in glioblastoma (GEINO 14–01)
Journal Article
Phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond 6 cycles in glioblastoma (GEINO 14–01)
Journal Article
Polymorphisms in ABCB1 and CYP19A1 genes affect anastrozole plasma concentrations and clinical outcomes in postmenopausal breast cancer patients
Journal Article
Preliminary results for the combination of docetaxel, oxaliplatin and capecitabine as first-line treatment for metastatic oesophagogastric cancer
Journal Article
Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE)
Journal Article
Primary melanoma of the vagina. A clinical case
Journal Article
Quimioterapia intraperitoneal en cáncer de ovario
Journal Article
Randomized crossover pharmacokinetic evaluation of subcutaneous versus intravenous granisetron in cancer patients treated with platinum-based chemotherapy
Journal Article
Real-world data of fulvestrant as first-line treatment of postmenopausal ER+ metastatic breast cancer
Journal Article
Safe Care and Medication Intake Provided by Caregivers at Home: Reality Care Study Protocol
Journal Article
Safety of eribulin as third-line chemotherapy in HER2– advanced breast cancer pre-treated with taxanes and anthracyclines (OnSITE study)
Journal Article
Single-arm, multicentre trial evaluating the safety of eribulin in third-line chemotherapy for HER2– metastatic breast cancer (ONCOSUR 2012–02)
Journal Article
Thyroid Transcription Factor 1 (TTF1) as a Predictive Biomarker for Pemetrexed-Based Chemotherapy in Non-Squamous NSCLC
Journal Article
Tratamiento hormonal del cáncer de mama
Journal Article
Use of bevacizumab as a first‐line treatment for metastatic breast cancer
Journal Article
Spanish Group of Oncology Aesthetic Medicine (GEMEON)
Spanish Group of Sarcoma (GEIS)
Spanish Group of Breast Cancer (SOLTI)
Spanish Group of Lung Cancer (GECP)
Spanish Group of Brain Tumours (GEINO)
Spanish Group of Breast Cancer (GEICAM)
Spanish Group of Neuroendocrine Tumours (GETNE)
Spanish Group of Medical Oncology (SEOM)
Inglés
Intermedio
Español
Nativo
Vídeos de
Consulta el contenido multimedia de este profesional.
Hospitals
Hospital Universitario Ruber Juan Bravo
C/ Juan Bravo, 39 y 49
28006 Madrid
Artículos de
Consulta los últimos artículos en Tu canal de salud.
¿No tienes seguro de salud?
Con nuestros Planes de Salud Quirónsalud Connect tendrás un médico de medicina general todos los días las 24 horas. Y además gestor personal y medición facial de constantes vitales.